Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01545505
Recruitment Status : Unknown
Verified February 2013 by Centre Hospitalier Universitaire de Nice.
Recruitment status was:  Recruiting
First Posted : March 6, 2012
Last Update Posted : February 21, 2013
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice

December 8, 2011
March 6, 2012
February 21, 2013
October 2012
October 2013   (Final data collection date for primary outcome measure)
Attentional score [ Time Frame: baseline at the first visit (T0), at 6 months, at 9 months ]
Go-No/Go and visual search tests
Same as current
Complete list of historical versions of study NCT01545505 on Archive Site
memory (Grober and Buschke) [ Time Frame: baseline at the first visit (T0), at 6 months, at 9 months ]
Grober and Buschke memory tests
Same as current
Not Provided
Not Provided
Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse
Early Diagnosis of Risk of Post-Traumatic Stress Disorder (PTSD) Relapse in Children and Their Families
Relapse of post-traumatic stress disorder (PTSD) remains challenging. In addition, factors predicting PTSD relapse are still unknown. The aim of this study is to examine whether clinical and neuropsychological changes (e.g., attentional bias toward aversive cues) that characterized PTSD can be observed in people with past PTSD (children and their families) and whether these persistent changes are predictive of PTSD relapse.

One of the great challenges in Psychotraumatology is the high risk (20-40%) of post-traumatic stress disorder (PTSD) relapse, which markers remain understudied. Identification of these markers is of particular interest for the development of strategies to prevent relapse. Based on clinical and experimental data, it appears that (i) the so-called residual clinical symptoms (such as sleep disturbance, irritability) and (ii) the neuropsychological dysfunctions (cognitive difficulties), persisting after remission, may constitute markers of PTSD relapse. Moreover, all of these potential markers have also been linked with dysfunctions, persisting or reoccurring, in the prefrontal cortex after remission.

The main objective of this study is to identify these clinical and neuropsychological markers of PTSD relapse in children and their families. The secondary objective is to demonstrate the link between prefrontal dysfunctions and relapse.

This longitudinal study will include 4 experimental groups:

  • 30 children with PTSD
  • 30 children with past PTSD (children in remission)
  • 30 parents of children with PTSD
  • 30 parents of children with past PTSD The first visit is planned during the symptomatic phase (T0). The second visit (T1) is planned at the end of the symptomatic phase (or 6 months later T0). The last visit is planned 3-months after T1.

The psychological assessment will include:

A structured interview with a psychiatrist An assessment of PTSD symptoms (IES-R, CPTS-RI for children) An assessment of the co-morbidity (STAI C and CDI for children, STAI A-B, BDI for adults).

An evaluation of the social life (EAS for children and SAS-SR for adults).

The neuropsychological assessment will include:

An evaluation of the attentional treatment (Go-No / go and visual search) An evaluation of executive functions (TMT A and B) A brief evaluation of the IQ (items memory of figures, matrix and resemblance) An evaluation of the memory (Grober and Buschke) Tests include an adult and children versions that are validated. All studies will be conducted at the Nice University Hospital, Tours University Hospital and Toulouse University Hospital.

Not Applicable
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Post Traumatic Stress Disorder (PTSD)
Behavioral: Neuropsychological assessment

A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.

A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test.

  • In remission phase of PTSD
    Patients having suffered from PTSD in the past and in remission od PTSD and their parents
    Intervention: Behavioral: Neuropsychological assessment
  • Activ PTSD
    patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
    Intervention: Behavioral: Neuropsychological assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
July 2014
October 2013   (Final data collection date for primary outcome measure)

For children

Inclusion Criteria:

  • Children (9/18 years)
  • Patients who have lived a traumatic event (physical assault and road accident) and who have a PTSD.
  • French speaker.
  • Participants must sign the informed consent and they must be affiliated to the social insurance.

Exclusion Criteria

  • Children who have a neurological pathology.
  • Children who have brain damage or brain-injured
  • Subject having participated in a biomedical research in three months preceding the inclusion
Sexes Eligible for Study: All
9 Years to 18 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Centre Hospitalier Universitaire de Nice
Centre Hospitalier Universitaire de Nice
Not Provided
Principal Investigator: Michel BENOIT, M.D.,PhD Psychiatrie, Hôpital Pasteur, CHU de NICE
Principal Investigator: Wissam EL HAGE, M.D, PhD Psychiatrie, CHU de TOURS
Principal Investigator: Frédérique JOVER, M.D. CAP, Hôpital St ROCH, CHU de NICE
Principal Investigator: Florence ASKENAZY, M.D. Fondation Lenval, NICE
Principal Investigator: Philippe BIRMES, M.D. Psychiatrie, CHU de TOULOUSE
Principal Investigator: Virginie BUISSE, M.D. CAP, Hôpital St Roch, CHU de NICE
Centre Hospitalier Universitaire de Nice
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP